Round Cell Liposarcoma
Associated Genetic Biomarkers
NCI Definition: A poorly differentiated liposarcoma, characterized by the presence of solid sheets of primitive round mesenchymal cells and the absence of myxoid stroma. 
There are 3 clinical trials for round cell liposarcoma, of which 2 are open and 1 is completed or closed. Of the trials that contain round cell liposarcoma as an inclusion criterion, 2 are phase 1 (1 open) and 1 is phase 2 (1 open).
DDIT3 and FUS are the most frequent gene inclusion criteria for round cell liposarcoma clinical trials .
Adp-a2m4cd8, ny-eso-1 t cell receptor-activated autologous t cells, and cyclophosphamide are the most common interventions in round cell liposarcoma clinical trials.
Significant Genes in Round Cell Liposarcoma
DDIT3 is an inclusion eligibility criterion in 1 clinical trial for round cell liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains DDIT3 status and round cell liposarcoma as inclusion criteria, 1 is phase 2 (1 open) .
FUS is an inclusion eligibility criterion in 1 clinical trial for round cell liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains FUS status and round cell liposarcoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.